Trestle Biotherapeutics

Trestle Biotherapeutics is a biotechnology company located in San Diego, California, focused on the development of bioengineered kidneys designed to supplement renal function for patients suffering from kidney failure. As a participant in the Y Combinator W21 batch, the company operates within the Healthcare and Industrial Bio sectors, primarily in the United States and Canada. Trestle Biotherapeutics is in its early stages of development but has already garnered significant recognition and support. It received a $1 million prize from the KidneyX Innovation Accelerator’s Artificial Kidney Prize program and is part of the Wellcome Leap HOPE program. The company has been highlighted by TechCrunch as a top biotech company at Y Combinator’s W21 Demo Day and is backed by notable investors including Y Combinator and Formic Ventures.